Mohadeseh Mehrabian has completed her PhD at the University of Toronto under the supervision of Dr. Gerold Schmitt-Ulms in 2017. In her doctoral work, Dr. Mehrabian has combined CRISPR-Cas9 genetic modification skills with quantitative proteomics to reveal a deep knowledge of prion protein biology, a key molecule involved in neurodegenerative diseases. These findings led to identification of drug targets for Alzheimer’s and prion diseases. Her postdoctoral work in Dr. Schmitt-Ulm’s laboratory involved characterizing a candidate drug and assessing the clinical viability of this compound.
As a postdoctoral scholar in Dr. Prusiner's laboratory, Dr. Mehrabian’s research aims to develop mechanism-driven therapeutic drug screens for neurodegenerative diseases such as Alzheimer’s disease.